Navigation Links
Advanced blood analysis may speed diagnosis of heart attacks
Date:9/9/2008

Someday doctors may be able to use a blood test to confirm within minutes, instead of hours, if a patient is having a heart attack, allowing more rapid treatment that could limit damage to heart muscle. A study led by investigators from Massachusetts General Hospital (MGH) and the Broad Institute of Harvard and MIT reports that a new technique that measures hundreds of molecular markers in the blood can identify those released when cardiac tissue is injured by a lack of oxygen. The report will appear in the October Journal of Clinical Investigation and has received early online release.

"Right now there are no blood markers for reversible myocardial injury in clinical use, and the only available markers are not detectable until hours after the onset of tissue damage. Because our treatments for heart attacks are most effective in the first hours after symptoms occur, these newly identified markers could help us apply treatments sooner and help more patients," says the study's senior author Robert Gerszten, MD, of the MGH Division of Cardiology and Center for Immunology and Inflammatory Diseases.

Every metabolic activity in the body results in the production of metabolites, molecules released in often-minute quantities. A blood sample contains hundreds of these metabolites that could provide a chemical 'snapshot' of an individual's heath status. But the technology to assess metabolite levels is in the early stages, as is the understanding of their significance. For instance, how much metabolite levels normally vary between healthy individuals and factors that influence those variations is still unknown.

In the current study, the research team took advantage of a procedure that is, in essence, a planned heart attack. In a condition called hypertrophic cardiomyopathy, bloodflow out of the heart is obstructed by a massive thickening of the wall between the left and right sides. This tissue overgrowth can be treated with a technique called septal ablation pioneered by Michael Fifer, MD, of MGH Cardiology that destroys the excess tissue, a scenario that mimics the damage that happens to heart muscle when its blood supply is cut off. Taking blood samples before and after patients receive this procedure provides a unique window into metabolic changes that occur in response to the death of myocardial tissue, allowing study participants to act as their own controls.

The researchers analyzed blood samples from 36 patients taken before and at several time points after septal ablation. Using an advanced mass spectrometry system that can assess hundreds of metabolites in as little as 10 minutes, they were able to identify several that significantly changed right after the ablation process, a time period during which currently available markers remained unchanged. The changes seen in the first 10 minutes persisted an hour later, and analysis of blood from veins in the coronary circulation confirmed that the heart was the source of the changes.

Comparing the results of these 'planned' heart attacks with blood samples from patients with spontaneous coronary blockages found four metabolites that increased in response to ablation and also were elevated in patients with true heart attacks, confirming them as markers of myocardial damage. The researchers also examined whether these newly identified metabolites had any effect on the response of cultured animal heart cells to reduced oxygen and found that one metabolite increased cell death, while two others decreased it, possibly identifying a pathway for future therapies.

"This work is proof of principle that this new technology will work for diagnosis and may also help us find new targets for therapeutic intervention. Someday we may be able to reverse the damage from a heart attack with a 'cocktail' of protective metabolites," explains Gerszten, who is an associate professor of Medicine at Harvard Medical School and a senior associate member of the Broad Institute. The study was supported by grants from the National Institutes of Health, the Donald W. Reynolds Foundation, and the Leducq Foundation. The MGH has filed a patent for the use of metabolic biomarkers to assess and reverse the kind of cardiac damage produced in a heart attack.


'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer
3. Advanced Age No Bar to Liver Transplant
4. Oncologists are critical in managing psychiatric disorders in patients with advanced cancer
5. Advanced technologies aim to transform the coaching of top athletes
6. Mecklenburg EMS Introduces Most-Advanced Situational Training in America for Emergency Medical Personnel
7. Advanced Life Sciences Joins NASDAQ Capital Market
8. Experimental drug shows promise in advanced kidney cancer
9. TCS Healthcare Technologies Announces Full Integration of Case Management Adherence Guidelines into Acuity Advanced Care(TM) System
10. OCuSOFT Refutes Comparison Time-Kill Study Released by Advanced Vision Research
11. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
(Date:10/12/2017)... ... 2017 , ... Vohra Chief Medical Officer Dr. Shark Bird, ... nursing facility medical directors and other clinicians at various events in October. His ... many of these conferences we get to educate other physicians, facility nurses, corporate ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
(Date:10/10/2017)... EXTON, Pa. , Oct. 10, 2017   ... leader in innovative solutions for injectable drug administration, today ... of West,s ID Adapter for improving the intradermal administration ... the Fourth Skin Vaccination Summit in May 2017 by ... Team Lead, Polio Department, World Health Organization (WHO), and ...
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
Breaking Medicine Technology: